Wenjie Chen1, Deshen He2, Zuyun Li1, Xin Zhang1, Denghua Pan1, Gang Chen1. 1. Department of Pathology, First Affiliated Hospital of Guangxi Medical University 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, China. 2. Department of Neurology, Seventh Affiliated Hospital of Guangxi Medical University, Wuzhou Worker Hospital Wuzhou, Guangxi Zhuang Autonomous Region 530021, China.
Abstract
BACKGROUND: Accumulated studies have revealed that vascular endothelial growth factor (VEGF) plays an essential role in the progression of glioma, but the prognostic significance of VEGF expression for patients with glioma remains unknown. METHOD AND MATERIAL: A literature search of public databases (PubMed, ISI Web of Science, Science Direct, Cochrane Central Register of Controlled Trials, Wiley Online Library, China National Knowledge Infrastructure, China Biology Medicine disc, Chongqing VIP and Wan Fang Data) was conducted. A meta-analysis was performed to evaluate the association between the overexpression of VEGF and the survival for the glioma patients. Subsequently we evaluated the impact of VEGF expression on the pathological grade of glioma. RESULTS: A total of 32 articles with 2307 cases contributed to this analysis, of which 31 reported overall survival (OS) and 5 reported progression-free survival (PFS). In this meta-analysis, VEGF overexpression significantly identified the unfavorable outcome on OS (HR = 1.647, 95% CI: 1.324~2.048, P < 0.001, Z = 4.48) but not on PFS (HR = 1.021, 95% CI: 0.974~1.070, P = 0.393). Subgroup analyses also revealed that high level of VEGF was associated with the poor OS for the patients with glioma according to region, case number, specimen type, method to detect VEGF and statistical method. Furthermore, the significant correlation was achieved between VEGF expression and the pathological grade of glioma (r = 0.307, P < 0.001). CONCLUSION: This study suggests that VEGF expression is significantly correlated with the glioma progression and may be a valuable prognostic factor on OS for the glioma patients.
BACKGROUND: Accumulated studies have revealed that vascular endothelial growth factor (VEGF) plays an essential role in the progression of glioma, but the prognostic significance of VEGF expression for patients with glioma remains unknown. METHOD AND MATERIAL: A literature search of public databases (PubMed, ISI Web of Science, Science Direct, Cochrane Central Register of Controlled Trials, Wiley Online Library, China National Knowledge Infrastructure, China Biology Medicine disc, Chongqing VIP and Wan Fang Data) was conducted. A meta-analysis was performed to evaluate the association between the overexpression of VEGF and the survival for the gliomapatients. Subsequently we evaluated the impact of VEGF expression on the pathological grade of glioma. RESULTS: A total of 32 articles with 2307 cases contributed to this analysis, of which 31 reported overall survival (OS) and 5 reported progression-free survival (PFS). In this meta-analysis, VEGF overexpression significantly identified the unfavorable outcome on OS (HR = 1.647, 95% CI: 1.324~2.048, P < 0.001, Z = 4.48) but not on PFS (HR = 1.021, 95% CI: 0.974~1.070, P = 0.393). Subgroup analyses also revealed that high level of VEGF was associated with the poor OS for the patients with glioma according to region, case number, specimen type, method to detect VEGF and statistical method. Furthermore, the significant correlation was achieved between VEGF expression and the pathological grade of glioma (r = 0.307, P < 0.001). CONCLUSION: This study suggests that VEGF expression is significantly correlated with the glioma progression and may be a valuable prognostic factor on OS for the gliomapatients.
Authors: Marc R J Carlson; Whitney B Pope; Steve Horvath; Jerome G Braunstein; Phioanh Nghiemphu; Cho-Lea Tso; Ingo Mellinghoff; Albert Lai; Linda M Liau; Paul S Mischel; Jun Dong; Stanley F Nelson; Timothy F Cloughesy Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: Jeannette R Flynn; Libo Wang; David L Gillespie; Gregory J Stoddard; Jason K Reid; Jason Owens; Grant B Ellsworth; Karen L Salzman; Anita Y Kinney; Randy L Jensen Journal: Cancer Date: 2008-09-01 Impact factor: 6.860
Authors: Viveka Nand Yadav; David Altshuler; Padma Kadiyala; Daniel Zamler; Andrea Comba; Henry Appelman; Patrick Dunn; Carl Koschmann; Maria G Castro; Pedro R Löwenstein Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300
Authors: Katharina Burmeister; Luca Quagliata; Mariacarla Andreozzi; Serenella Eppenberger-Castori; Matthias S Matter; Valeria Perrina; Rainer Grobholz; Wolfram Jochum; Daniel Horber; Peter Moosmann; Frank Lehmann; Dieter Köberle; Charlotte K Y Ng; Salvatore Piscuoglio; Luigi Tornillo; Luigi M Terracciano Journal: PLoS One Date: 2017-04-12 Impact factor: 3.240
Authors: Ararat Chakhoyan; Jingwen Yao; Kevin Leu; Whitney B Pope; Noriko Salamon; William Yong; Albert Lai; Phioanh L Nghiemphu; Richard G Everson; Robert M Prins; Linda M Liau; David A Nathanson; Timothy F Cloughesy; Benjamin M Ellingson Journal: Sci Rep Date: 2019-02-26 Impact factor: 4.379